Tectonic Therapeutic (TECX) Consolidated Net Income (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Consolidated Net Income of -$53.8 million for Q1 2026, down 236.16% year-over-year from $39.5 million in Q1 2025, and down 179.85% quarter-over-quarter from -$19.2 million in Q4 2025.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Consolidated Net Income (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Consolidated Net Income for 10 consecutive years, with -$53.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 236.16% year-over-year to -$53.8 million; the TTM figure through Mar 2026 stood at -$112.0 million (down 99.14% YoY), while the FY2025 annual figure was -$74.2 million, down 33.65% from the prior year.
- Consolidated Net Income fell to -$53.8 million in Q1 2026 per TECX's latest filing, from -$19.2 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$9.3 million in Q4 2023 and bottomed at -$53.8 million in Q1 2026.
- Historically, Consolidated Net Income has averaged -$20.5 million across 5 years, with a median of -$19.0 million in 2025.
- Annual changes were most pronounced in 2023 — Consolidated Net Income surged 64.08% — and 2026, when it plunged 236.16%.
- Tectonic Therapeutic's Consolidated Net Income stood at -$25.8 million in 2022, then soared by 64.08% to -$9.3 million in 2023, then dropped by 6.46% to -$9.9 million in 2024, then plunged by 94.71% to -$19.2 million in 2025, then plunged by 179.85% to -$53.8 million in 2026.
- Business Quant data shows TECX's Consolidated Net Income at -$53.8 million in Q1 2026, -$19.2 million in Q4 2025, and -$19.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tectonic Therapeutic | 584.94 Mn | 584.94 Mn | - | -22.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.29 Mn |
| Mar 31, 2026 | -25.13 Mn |
| Dec 31, 2025 | -2.91 Mn |
| Sep 30, 2025 | -19.04 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Dec 31, 2024 | -197,000.00 |
| Sep 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -12.74 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | -10.05 Mn |
| Jun 30, 2023 | -10.45 Mn |
| Mar 31, 2023 | -24.97 Mn |
| Dec 31, 2022 | -25.01 Mn |
| Sep 30, 2022 | -22.87 Mn |
| Jun 30, 2022 | -28.06 Mn |
| Mar 31, 2022 | -29.83 Mn |
| Dec 31, 2021 | -28.21 Mn |
| Sep 30, 2021 | -32.62 Mn |